Moreover, HDAC inhibitors exhibit potent anticancer effects in hematological malignancies and hold promise as potential therapeutic agents for treating colorectal cancer (43) and triple-negative breast cancer (44). The gene discussed is HDAC9; the disease is triple-negative breast carcinoma.